On Monday, Terex Corporation (NYSE:TEX)’s shares inclined 1.01% to $24.98.
Terex Corporation (TEX) declared that its Board of Directors declared a quarterly dividend of $0.06 per common share. The dividend is to be paid on June 19, 2015 to all stockholders of record as of the close of business on June 10, 2015.
Terex Corporation operates as a lifting and material handling solutions company. Its Aerial Work Platforms segment designs, manufactures, services, and markets aerial work platform equipment, telehandlers, and light towers, in addition to related components and replacement parts under Terex and Genie names.
Keurig Green Mountain Inc (NASDAQ:GMCR)’s shares dropped -0.01% to $86.23.
Dunkin’ Brands Group, Inc., (DNKN), The J.M. Smucker Company (SJM) and Keurig Green Mountain, Inc. (Keurig) (GMCR) recently declared that Dunkin’ K-Cup®* pods are now accessible for sale at thousands of retailers nationwide for the first time. As part of a contract between the three companies first declared in February, Smucker will distribute and market Dunkin’ K-Cup® pods exclusively to grocery chains, mass merchandisers, club stores, drug stores, dollar stores and home improvement stores. Keurig will distribute and market Dunkin’ K-Cup® pods exclusively to specialty stores such as Bed Bath & Beyond, Kohl’s and Macy’s, in addition to office supply retailers such as Staples and Office Depot starting this summer.
Dunkin’ K-Cup® pods are also now accessible for sale online at OnlineStore.Smucker.com and Keurig.com, in addition to DunkinDonuts.com. The Dunkin’ K-Cup® varieties accessible online and in grocery, mass merchandise, club, drug and other retailers nationwide comprise Original Blend, Decaf, Hazelnut, French Vanilla and Chocolate Glazed Donut.
A coupon for $1.50 off the purchase of any two packages of Dunkin’ K-Cup® pods or packaged coffee at grocery stores and other retailers nationwide will be accessible in select Sunday newspapers on June 14, 2015.
Keurig Green Mountain, Inc. produces and sells specialty coffee, coffeemakers, teas, and other beverages in the United States and Canada. It sources, produces, and sells coffee, hot cocoa, teas, and other beverages under various brands in K-Cup, Vue, Rivo, K-Carafe, and Bolt portion packs brands; and coffee in traditional packaging, counting bags and fractional packs, in addition to offers whole bean and ground coffee in bags, fractional packages, and cans.
At the end of Monday’s trade, Big Lots, Inc. (NYSE:BIG)‘s shares surged 2.26% to $44.89.
Big Lots, Inc. (BIG) declared that, on May 28, 2015, our Board of Directors declared a quarterly cash dividend of $0.19 per common share.
The dividend will be paid on June 26, 2015, to shareholders of record as of the close of business on June 12, 2015.
Big Lots, Inc., through its auxiliaries, operates as a non-traditional, discount retailer in the United States. The company offers products under various merchandising categories, such as food category that comprises beverage and grocery, candy and snacks, and specialty foods departments; consumables category, which comprises health and beauty, plastics, paper, chemical, and pet departments; soft home category that comprises of fashion bedding, utility bedding, bath, window, decorative textile, and area rugs departments; hard home category, counting small appliances, table top, food preparation, stationery, greeting cards, tools, paint, and home maintenance departments; and furniture and home décor category compriseing of upholstery, mattress, ready-to-assemble, case goods, home décor, and frames departments.
Peregrine Pharmaceuticals (NASDAQ:PPHM), ended its Monday’s trading session with 0.01% loss, and closed at $1.41.
Peregrine Pharmaceuticals (PPHM) a biopharmaceutical company focused on oncology and the treatment of lung and breast cancers through the development of bavituximab, a novel immunotherapy presently in Phase III, recently offered a corporate update on its immuno-oncology pipeline, its wholly-owned contract manufacturing business, Avid Bioservices, in addition to anticipated forthcoming milestones. This update outlines the expansion of the bavituximab clinical pipeline with a focus on exploring expanded indications and combinations in lung and breast cancers. These new trials build on recently published clinical data of bavituximab in combination with paclitaxel in HER2 negative breast cancer and clinical translational and preclinical data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that support the potential combination of bavituximab with the anti-PD-1 checkpoint inhibitor, nivolumab (marketed as Opdivo(R)). These clinical trials are predictable to start enrollment later this year.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
